Results 161 to 167 of about 740 (167)

Tagraxofusp in myeloid malignancies

Hematological Oncology
Francesco Mendicino, Massimo Gentile, Antonella Bruzzese   +2 more
exaly  

Pacritinib/Ruxolitinib/Tagraxofusp

Reactions Weekly
openaire   +1 more source

Tagraxofusp für Therapie seltener hämatologischer Neoplasie

InFo Hämatologie + Onkologie, 2019
openaire   +1 more source

Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations

Leukemia and Lymphoma
Andrew Lane, David Rizzieri, Raajit Rampal   +2 more
exaly  

FDA approves tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm

Case Medical Research, 2018
openaire   +2 more sources

Tagraxofusp, a first‐in‐class CD123‐targeted agent: Five‐year postapproval comprehensive review of the literature

Cancer
Naveen Pemmaraju, Wei Ying Jen, Marina Konopleva   +2 more
exaly  

CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123

Leukemia Research
Brent Tan, Naveen Pemmaraju, Atif Saleem   +2 more
exaly